2025
Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers
Zakeri K, Wren S, Shang T, Yu Y, Chen L, Shamseddine A, Safavi A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers. Head & Neck 2025 PMID: 40515499, DOI: 10.1002/hed.28217.Peer-Reviewed Original ResearchP16-negative oropharyngeal cancerNodal recurrenceLocoregional recurrenceP16-negativeDistant recurrenceOropharyngeal cancerHead and neck cancer patientsRadiation doseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent chemoradiationRadiotherapy doseMedian followConsecutive patientsTreatment toxicityImprove quality of lifeConsecutive cohortCancer patientsRecurrenceQuality of lifeHypopharyngealDosePatientsOutcome measures
2024
Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis
Buqué A, Bloy N, Petroni G, Jiménez-Cortegana C, Sato A, Iribarren C, Yamazaki T, Galassi C, Hensler M, Bhinder B, Guarracino A, Rippon B, Beltran-Visiedo M, Soler-Agesta R, Pannellini T, Fucikova J, Demaria S, Zhou X, Elemento O, Formenti S, Galluzzi L. Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis. Journal Of The National Cancer Institute 2024, 117: 934-947. PMID: 39661487, PMCID: PMC12058254, DOI: 10.1093/jnci/djae329.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRadiation therapyFocal RTOverall survivalMammary carcinogenesisPD-1Impact of radiotherapy doseMouse modelPD-1 blockerRT plus immunotherapyPrimary tumor growthPrimary disease controlIncrease local controlCheckpoint inhibitorsRadiotherapy doseHypofractionated RTOS benefitTumor burdenPrimary tumorBreast cancerTumor growthNeoplastic lesionsLocal controlICI sensitivityEffective immunityOutcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers
Zakeri K, Shang T, Yu Y, Chen L, Shamseddine A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e807. DOI: 10.1016/j.ijrobp.2024.07.1772.Peer-Reviewed Original ResearchP16-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomasOropharyngeal squamous cell carcinomaDistant recurrenceSquamous cell carcinomaNodal recurrenceRadiotherapy doseLocoregional recurrenceP16 statusCell carcinomaHypopharynx cancerP16-negative oropharyngeal cancerHead and neck cancer patientsRadiation doseElective nodal volumesP16-negative diseaseNode-positive diseaseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent cetuximabConcurrent chemotherapyLocoregional controlMedian followNodal disease
2022
Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas
Tom MC, Milano MT, Chao ST, Soltys SG, Knisely JPS, Sahgal A, Nagpal S, Lo SS, Jabbari S, Wang TJC, Ahluwalia MS, Simonson M, Palmer JD, Gephart MH, Halasz LM, Garg AK, Chiang VLS, Chang EL. Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy And Oncology 2022, 170: 79-88. PMID: 35367527, DOI: 10.1016/j.radonc.2022.03.018.Peer-Reviewed Original ResearchConceptsLow-grade gliomasAppropriate use criteriaGrade 2 gliomasGrade 3 gliomasPostoperative managementGrade gliomasIDH-mutant oligodendrogliomasPostoperative therapyRadiotherapy doseAmerican Radium Society Appropriate Use CriteriaGrade 2Gross total surgical resectionImmediate adjuvant therapyHigh-risk featuresType of chemotherapyLow-risk featuresAppropriate treatment optionsIDH-mutant astrocytomasAdjuvant therapyModality therapySurgical resectionConsensus guidelinesTreatment optionsClose surveillanceConsensus recommendationsEvaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2021
Longitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Rodwin RL, Chen Y, Yasui Y, Leisenring WM, Gibson TM, Nathan PC, Howell RM, Krull KR, Mohrmann C, Hayashi RJ, Chow EJ, Oeffinger KC, Armstrong GT, Ness KK, Kadan-Lottick NS. Longitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1536-1545. PMID: 34099519, PMCID: PMC8523186, DOI: 10.1158/1055-9965.epi-21-0154.Peer-Reviewed Original ResearchConceptsChildhood Cancer Survivor StudyChildhood cancer survivorsCancer Survivor StudyNeuromuscular dysfunctionCumulative incidenceSpinal radiotherapyYears postdiagnosisCancer survivorsPrevalence ratiosSurvivor StudyCentral nervous system tumorsLong-term survivorsNervous system tumorsLater obesityRadiotherapy doseCNS tumorsSystem tumorsChildhood cancerMultivariable modelPlatinum exposureDysfunctionLongitudinal evaluationSurvivorsPrevalenceRadiation exposure
2015
Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base
Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base. Cancer 2015, 121: 4141-4149. PMID: 26280559, DOI: 10.1002/cncr.29652.Peer-Reviewed Original ResearchConceptsImproved overall survivalNational Cancer Data BaseOverall survivalPancreatic adenocarcinomaAdjuvant chemotherapyR0 resectionR1 resectionPN1 diseaseNational cohortSubset analysisPropensity scoreAddition of radiotherapyMedian radiotherapy doseOutcome of chemotherapyLarge national cohortPT1-3N0CRT groupClinicopathologic characteristicsCRT patientsRandomized comparisonCox regressionRadiotherapy doseOptimal treatmentPancreatic cancerUnivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply